Reiko Akizuki

End-of-life preferences of the general public: Results from a Japanese national survey.

N. Ikegami, K. Yoshimura, S. Nozaki, 2015, Health Policy.

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance

A. Fujino, S. Tsujioka, Ai Omi, 2022, Journal of Clinical and Experimental Hematopathology.